Last updated on May 2018

A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)


Brief description of study

PIONEER-II OPC trial is a prospective, multicenter, single-arm registry trial. 1000 subjects from approximately 40 interventional cardiology centers will be enrolled to evaluate the target lesion failure(TLF) as the primary endpoint at 1 year. And all the subjects will be followed up to 5 years to attain the data of the secondary endpoints.

Detailed Study Description

Realizing even more uniform and complete endothelial coverage, BuMA Supreme biodegradable drug coating coronary stent system comprises a new generation of biodegradable drug eluting stent under development by Sino medical science(SINOMED). BuMA Supreme reconfigures BuMA DES utilizing a high caliber cobalt chromium platform coated with rapidly degrading PLGA scaffold.

Clinical Study Identifier: NCT02698852

Contact Investigators or Research Sites near you

Start Over

Junbo Ge, Ph.D

Zhongshan Hospital
Shanghai, China

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.